Scientech Research LLC Makes New $285,000 Investment in R1 RCM Inc. (NASDAQ:RCM)

Scientech Research LLC purchased a new stake in shares of R1 RCM Inc. (NASDAQ:RCM) during the 2nd quarter, HoldingsChannel reports. The fund purchased 22,681 shares of the healthcare provider’s stock, valued at approximately $285,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of RCM. Capital International Investors lifted its stake in R1 RCM by 0.8% during the fourth quarter. Capital International Investors now owns 8,343,199 shares of the healthcare provider’s stock valued at $88,188,000 after purchasing an additional 67,485 shares during the last quarter. P2 Capital Partners LLC increased its holdings in shares of R1 RCM by 70,366.3% in the fourth quarter. P2 Capital Partners LLC now owns 3,535,294 shares of the healthcare provider’s stock valued at $37,368,000 after buying an additional 3,530,277 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in shares of R1 RCM by 4.5% during the 2nd quarter. Dimensional Fund Advisors LP now owns 3,154,888 shares of the healthcare provider’s stock valued at $39,624,000 after acquiring an additional 136,808 shares during the last quarter. Boston Partners boosted its stake in shares of R1 RCM by 4,976.6% during the 1st quarter. Boston Partners now owns 2,570,371 shares of the healthcare provider’s stock worth $32,784,000 after acquiring an additional 2,519,739 shares in the last quarter. Finally, First Light Asset Management LLC grew its holdings in shares of R1 RCM by 212.8% in the 1st quarter. First Light Asset Management LLC now owns 2,552,325 shares of the healthcare provider’s stock worth $32,874,000 after acquiring an additional 1,736,346 shares during the last quarter. Institutional investors own 61.10% of the company’s stock.

R1 RCM Price Performance

Shares of R1 RCM stock opened at $14.17 on Tuesday. The firm has a market cap of $5.97 billion, a price-to-earnings ratio of -177.13 and a beta of 0.84. The stock has a 50-day simple moving average of $13.92 and a 200-day simple moving average of $13.01. R1 RCM Inc. has a 52-week low of $8.87 and a 52-week high of $15.26. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.84 and a quick ratio of 1.84.

R1 RCM (NASDAQ:RCM) last posted its earnings results on Wednesday, August 7th. The healthcare provider reported ($0.02) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.03. R1 RCM had a negative net margin of 1.68% and a negative return on equity of 1.44%. The firm had revenue of $627.90 million during the quarter, compared to analysts’ expectations of $633.10 million. The firm’s revenue for the quarter was up 12.0% compared to the same quarter last year. On average, equities research analysts expect that R1 RCM Inc. will post -0.24 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

RCM has been the subject of several analyst reports. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $14.30 target price on shares of R1 RCM in a report on Tuesday, August 20th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $19.00 price objective on shares of R1 RCM in a research note on Friday, June 28th. Stephens downgraded shares of R1 RCM from an “overweight” rating to an “equal weight” rating in a research report on Thursday, August 1st. Deutsche Bank Aktiengesellschaft upped their price target on shares of R1 RCM from $14.00 to $16.00 and gave the company a “hold” rating in a research report on Tuesday, July 9th. Finally, TD Cowen reiterated a “hold” rating and set a $14.30 price objective (down from $20.00) on shares of R1 RCM in a research report on Monday, August 5th. Thirteen analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $15.41.

R1 RCM Profile

R1 RCM Inc provides technology-driven solutions for the financial performance and patient experience of health systems, hospitals, and physician groups. It provides operating partnership/end-to-end solutions, which manages multiple aspects of the revenue cycle to realize financial leverage and revenue improvement for hospital and physician customers.